Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
DUBLIN, Ireland, Oct. 12, 2016 -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the third quarter fiscal year 2016 on Tuesday, October 25, 2016. The Company has scheduled a conference call for that same day, Tuesday, October 25, 2016 at 11:00am ET (4:00pm BST) to discuss the results of the quarter.
Interested parties can access the call by dialing:
| USA: | 1-844-861-5499 | |||
| International: | 1-412-317-6581 | |||
| Conference ID #: | 10094363 | |||
A simultaneous webcast of the call can be accessed at:
https://www.webcaster4.com/Webcast/Page/1135/17674
A replay of the call can be accessed until November 1, 2016 by dialing:
| USA: | 1-877-344-7529 | ||
| International: | 1-412-317-0088 | ||
| Conference ID #: | 10094363 | ||
The webcast of the call will be available for 30 days at:
https://www.webcaster4.com/Webcast/Page/1135/17674
About Trinity Biotech plc
Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company's website: www.trinitybiotech.com.
Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.
Contact: Trinity Biotech plc Kevin Tansley (353)-1-2769800 E-mail: [email protected] Lytham Partners LLC Joe Diaz, Joe Dorame & Robert Blum 602-889-9700
